

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Rigdon Lentz

Serial No.: 09/699,003 Art Unit: 3761

Filed: October 26, 2000 Examiner: Leslie R. Deak

For: *METHODS AND COMPOSITIONS FOR TREATMENT OF CANCERS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including three (3) pages of Form PTO-1449, and copies of eighteen (18) of the documents cited therein, and a Request for Continued Examination to insure consideration.

Pursuant to the waiver in the notice entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications Filed After June 30, 2003" published on August 5, 2003 in 1273 OG 55, copies of the U.S. Patent Applications are not enclosed.

The requirement for a concise explanation of the relevance of the foreign language documents (marked with an asterisk (*) in the list below), under 37 C.F.R. § 1.98(a)(3) is satisfied by submitting an English language abstract, which is included in each document.

U.S.S.N.: 09/699,003
Filed: October 26, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits after filing a Request for Continued Examination (RCE). It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. No. 50-3129.

U.S. Patent Applications

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
2002/0114728	08-22-2002	Kulish, et al.	422/22
2003/0129130	07-10-2003	Guire, et al.	424/1.11

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 03/056896	07-17-2003	Molecular Staging Inc.	PCT
*2 130 069 (with English Abst.)	05-10-1999	Inst Ehlemento- organicheskikh S	RU

Publications

ADOLF and FRÜHBEIS, "Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity.", *Cytokine*, 4(3):180-184 (1992).

BJORNBERG, et al., "Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms", *Lymphokine Cytokine Res.*, 13(3):203-11 (1994).

COLMAN, et al., Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2nd Ed., Colman, R.W., et al., p. 242-267 (J.B.Lippincott, Philadelphia, PA 1987).

GADDUCCI, et al., "Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer", *Gynecol Oncol*, 58(2):184-8 (1995).

GRELL, et al., "The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor", *Proc Natl Acad Sci U S A.*, 95(2):570-5 (1998).

U.S.S.N.: 09/699,003
Filed: October 26, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

GROSEN, et al., "Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy", *Gynecol Oncol*, 50(1):68-77 (1993).

HASEGAWA, et al., "Increased soluble tumor necrosis factor receptor levels in the serum of elderly people", *Gerontology*, 46(4):185-8 (2000).

JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," *Arch Immunol Ther Exp (Warsz)*. 45(5-6):449-53 (1997).

JABLONSKA, et al., "Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients", *Eur Cytokine Netw*, 9(2):155-9 (1998).

* LAUCELLA, et al., "Papel de las citoquinas en la resistencia y patología durante la infección con *Trypanosoma cruzi*" *Revista Argentina de Microbiología*, 28:99-109 (1996) (with English Abstract).

MACALLAN, et al., "Development of a novel TNF alpha ligand-receptor binding assay for screening NATCHEM Libraries", *J Recept Signal Transduct Res*, 17(1-3):521-9 (1997). (with English Abstract)

MATSCHINER, et al., Current Advances in Vitamin K Research, pp. 135-140, (John W. Suttie, ed.) Elsevier Science Publishing Co., Inc., 1988.

NOPHAR, et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor", *EMBO J*, 9(10):3269-78 (1990).

ONSRUD, et al., "Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer", *Gynecol Oncol*, 57(2):183-7 (1995).

ONSRUD, et al., "Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer", *Tumour Biol*, 17(2):90-6 (1996).

TESAROVA, et al., "Soluble TNF and IL-2 receptors in patients with breast cancer", *Med Sci Monit*, 6(4):661-7 (2000).

U.S.S.N.: 09/699,003
Filed: October 26, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

/ Patrea L. Pabst /

Patrea L. Pabst
Reg. No. 31,284

Dated: November 10, 2009

PABST PATENT GROUP LLP
1545 Peachtree Street NE
Suite 320
Atlanta, GA 30309
(404) 879-2151 (Telephone)
(404) 879-2160 (Fax)